Summary of Tigermed (3347.HK) Conference Call Company Overview - **Company**: Tigermed (3347.HK) - **Market Cap**: HK$51,795 million (approximately US$6,654 million) [2] Industry Insights - **Industry**: Innovative drugs financing in China - **Growth Metrics**: - Total financing size for innovative drugs in China increased by 342% year-over-year (yoy) to Rmb18.0 billion in December 2025, marking a new high in the past three years [1] - Primary market financing for innovative drugs grew by 140% yoy to US$1.1 billion in December 2025 [1] - For the year 2025, total financing and primary market financing sizes rose by 38% and 25% yoy, respectively [1] Financial Performance and Projections - **Booking Growth**: Tigermed is expected to deliver higher new booking growth in 2026 compared to a mid-teens percentage in 2025 [1] Valuation - **Target Price**: HK$73.00, representing a potential upside of 72.0% from the current price of HK$42.44 [2] - **Expected Total Return**: 72.8%, including a dividend yield of 0.8% [2] - **Valuation Breakdown**: - HK$21.8 per share for clinical trial solutions - HK$35.8 per share for clinical-related and laboratory services - HK$0.4 per share for other services - HK$1.5 per share for net cash - HK$13.5 per share for investment income [11] Risks - **Downside Risks**: - Weaker-than-expected client orders - Intense market competition - Less-than-expected investment gains - Increased investment in AI potentially affecting operating profit margin (OPM) - Margin pressure due to overseas expansion - Lower-than-expected long-term margins with AI adoption [12] Conclusion - Tigermed is positioned to benefit from the significant growth in the innovative drugs financing sector in China, with strong projections for new bookings and a favorable valuation outlook. However, potential risks related to market dynamics and operational challenges must be monitored closely.